Femasys Files S-1/A for Equity Offering Amidst Funding Needs

TL;DR

**FEMY is diluting shareholders heavily to stay afloat, making it a high-risk bet on future product approvals and market penetration.**

AI Summary

Femasys Inc. (FEMY) filed an S-1/A on August 21, 2025, for an offering of up to 11,428,571 shares of common stock, pre-funded warrants for up to 11,428,571 shares, and common warrants for up to 11,428,571 shares, totaling up to 22,857,142 underlying shares. The offering aims to raise capital, with proceeds before expenses to be determined at pricing. The company's common stock was trading at $0.70 per share on the Nasdaq Capital Market as of August 18, 2025. Femasys is a biomedical innovator focusing on women's health, with products like FemaSeed Intratubal Insemination and FemBloc permanent birth control, which is approved in the European Union and undergoing U.S. clinical development. Key risks include the need for additional financing to fund commercialization and U.S. clinical trials, the ability to repay convertible notes due November 2025, and obtaining FDA approval for FemBloc in the U.S. The strategic outlook involves growing sales of FemaSeed in the U.S. and FemBloc in the EU, alongside advancing U.S. regulatory approval for FemBloc.

Why It Matters

This S-1/A filing is critical for Femasys Inc. as it seeks to raise substantial capital through an equity offering, which will directly impact its ability to fund ongoing operations, commercialization efforts for products like FemaSeed, and crucial U.S. clinical trials for FemBloc. For investors, the offering presents significant dilution risk, especially given the current $0.70 share price and the issuance of both common and pre-funded warrants. Employees and customers will be affected by the company's ability to secure this financing, as it underpins future product development and market expansion in the competitive women's health sector, where Femasys competes with established players in fertility and contraception.

Risk Assessment

Risk Level: high — The filing explicitly states 'Investing in our securities involves significant risks' and highlights the company's 'ability to obtain additional financing to fund commercialization of our products and fund our operations' and 'our ability to pay our convertible notes due November 2025, if not converted into common stock.' The offering of up to 11,428,571 shares of common stock, plus warrants for an additional 22,857,142 shares, indicates substantial potential dilution for existing shareholders, especially with the common stock trading at $0.70 per share on August 18, 2025.

Analyst Insight

Investors should exercise extreme caution due to the significant dilution risk and the company's explicit need for additional financing to continue operations and repay debt. Consider waiting for clearer signs of FDA approval for FemBloc and successful commercialization of FemaSeed before investing, as the current offering appears to be a lifeline rather than growth capital.

Key Numbers

• 11,428,571 — Shares of Common Stock Offered (Maximum number of common shares offered in the S-1/A)
• 11,428,571 — Pre-Funded Warrants Offered (Maximum number of pre-funded warrants offered)
• 11,428,571 — Common Warrants Offered (Maximum number of common warrants offered)
• 22,857,142 — Total Underlying Shares (Maximum shares underlying pre-funded and common warrants)
• $0.70 — Last Reported Sale Price (FEMY's stock price on Nasdaq Capital Market as of August 18, 2025)
• $0.001 — Par Value per Share (Par value of Femasys common stock)
• 2% — Underwriter Warrants Percentage (Percentage of shares/warrants sold that underwriters can purchase)
• November 2025 — Convertible Notes Due Date (Maturity date for Femasys's convertible notes)

Key Players & Entities

• Femasys Inc. (company) — Registrant and biomedical innovator
• Kathy Lee-Sepsick (person) — President and Chief Executive Officer of Femasys Inc.
• Dechert LLP (company) — Legal counsel for Femasys Inc.
• Nasdaq Capital Market (regulator) — Stock exchange where FEMY is listed
• Jones Laidlaw & Company (UK) Ltd. (company) — Bookrunner for the offering
• SEC (regulator) — Securities and Exchange Commission
• FDA (regulator) — U.S. Food and Drug Administration
• FemBloc (company) — Femasys's U.S. product candidate for permanent birth control
• FemaSeed (company) — Femasys's intratubal insemination product

FAQ

Risk Factors

• Need for Additional Financing [high — financial]: The company explicitly states its need for substantial additional capital to fund its commercialization efforts for FemaSeed and FemBloc, as well as ongoing U.S. clinical trials for FemBloc. Failure to secure this financing could significantly impede its strategic objectives and operational capabilities.
• Convertible Note Maturity [high — financial]: Femasys has convertible notes maturing in November 2025. The company's ability to repay these notes, or to refinance them, is a critical near-term financial risk. The S-1/A filing suggests that the proceeds from this offering may be used to address these obligations.
• FDA Approval for FemBloc [high — regulatory]: The commercial success of FemBloc in the United States is contingent upon obtaining FDA approval. The S-1/A highlights that FemBloc is currently undergoing U.S. clinical development, indicating that regulatory hurdles remain significant and approval is not guaranteed.
• Commercialization Challenges [medium — operational]: Femasys faces the challenge of scaling its commercial operations for both FemaSeed in the U.S. and FemBloc in the EU. This includes market penetration, sales force development, and distribution, all of which require significant investment and execution risk.
• Market Adoption of New Technologies [medium — market]: The company's products, particularly FemBloc, represent innovative solutions in women's health. However, market adoption of novel medical devices can be slow and unpredictable, influenced by physician acceptance, patient demand, and reimbursement landscapes.

Industry Context

Femasys operates in the highly competitive and regulated women's health and biomedical innovation sector. The market is characterized by a growing demand for advanced reproductive health solutions and contraceptive technologies. Key trends include the development of less invasive procedures and personalized medicine approaches. Competitors range from large pharmaceutical companies to specialized medical device manufacturers, all vying for market share and regulatory approvals.

Regulatory Implications

The company faces significant regulatory scrutiny, particularly from the FDA for its FemBloc product in the U.S. Obtaining necessary approvals is a critical gating item for market entry and commercial success. Compliance with evolving healthcare regulations and reimbursement policies in both the U.S. and EU is essential for sustained operations.

What Investors Should Do

1. Monitor FDA progress for FemBloc
2. Assess capital raising success and use of proceeds
3. Evaluate convertible note refinancing or repayment plan
4. Analyze market adoption rates for FemaSeed and FemBloc

Key Dates

• 2025-11-01: Convertible Notes Maturity — Investors are closely watching Femasys's ability to meet its convertible note obligations in November 2025, as failure to do so could trigger significant financial distress or dilution.
• 2025-08-21: S-1/A Filing — This filing provides updated information on the company's financial position, business strategy, and risks associated with its proposed offering, signaling active capital-raising efforts.

Glossary

S-1/A

An amended registration statement filed with the U.S. Securities and Exchange Commission (SEC) for a public offering of securities. The 'A' indicates it's an amendment to a previously filed S-1. (This is the primary document detailing Femasys's offering, business, and risks.)

Pre-funded Warrants

Warrants that allow the holder to purchase a share of common stock at a nominal exercise price (e.g., $0.001). They are typically offered in lieu of common stock to investors who may not wish to exceed certain ownership thresholds or to provide immediate exercisability. (Included in the offering, these suggest a strategy to accommodate certain investor types and potentially increase immediate participation.)

Common Warrants

Options that give the holder the right, but not the obligation, to purchase shares of common stock at a specified exercise price within a certain timeframe. (These are part of the offering structure, potentially providing additional upside for investors and acting as an incentive for underwriters.)

Intratubal Insemination

A method of assisted reproduction where sperm is placed directly into the fallopian tubes. (This is the technology behind Femasys's FemaSeed product, indicating the company's focus on reproductive health solutions.)

Year-Over-Year Comparison

As this is an S-1/A filing, it represents an initial or amended registration for an offering. Therefore, a direct comparison of key metrics like revenue growth, margin changes, or specific financial performance against a prior year's filing is not applicable in the traditional sense. The focus is on presenting the company's current state and future plans for investors in this offering, highlighting the need for capital and the associated risks.

Key Financial Figures

• $0.001 — 1 shares of our common stock, par value $0.001 per share ("common stock"), and common
• $0 — d to the public in this offering, minus $0.0001, and the exercise price of each pr
• $0.0001 — rice of each pre-funded warrant will be $0.0001 per share. The pre-funded warrants will
• $0.70 — stock on the Nasdaq Capital Market was $0.70 per share. The actual number of securit
• $10 million — ated to purchase, up to an aggregate of $10 million of shares of the Company's common stock
• $10 m — ment for an aggregate purchase price of $10 million, (iii) the date on which the Comp

Filing Documents

• ny20053452x7_s1a.htm (S-1/A) — 525KB
• ny20053452x7_ex1-1.htm (EX-1.1) — 221KB
• ny20053452x7_ex4-10.htm (EX-4.10) — 90KB
• ny20053452x7_ex4-11.htm (EX-4.11) — 92KB
• ny20053452x7_ex4-12.htm (EX-4.12) — 96KB
• ny20053452x7_ex5-1.htm (EX-5.1) — 13KB
• ny20053452x7_ex23-1.htm (EX-23.1) — 3KB
• ny20053452x7_exfees.htm (EX-FILING FEES) — 38KB
• logo_femasys.jpg (GRAPHIC) — 43KB
• logo_kpmg.jpg (GRAPHIC) — 2KB
• ny20053452x7_ex5-1img01.jpg (GRAPHIC) — 20KB
• ny20053452x7_ex23-1img01.jpg (GRAPHIC) — 21KB
• 0001140361-25-032230.txt ( ) — 1342KB
• ny20053452x7_exfees_htm.xml (XML) — 11KB

RISK FACTORS

RISK FACTORS 8 CAPITALIZATION 12

DILUTION

DILUTION 13 DIVIDEND POLICY 15

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 16 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO HOLDERS OF COMMON STOCK, PRE-FUNDED WARRANTS AND COMMON WARRANTS 19

USE OF PROCEEDS

USE OF PROCEEDS 25

UNDERWRITING

UNDERWRITING 26 LEGAL MATTERS 34 EXPERTS 34 WHERE YOU CAN FIND MORE INFORMATION 34 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 35 i TABLE OF CONTENTS CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus and the documents we have filed with the Securities and Exchange Commission the ("SEC") that are incorporated by reference herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this prospectus and the documents incorporated by reference herein, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus and the documents incorporated by reference herein are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, fi

View Full Filing

View this S-1/A filing on SEC EDGAR